A validation of the use of names to screen for risk of chronic hepatitis B in Victoria, Australia, 2001 to 2010

MacLachlan, Jennifer H; Wang, Y J; Cowie, Benjamin C

doi:10.2807/1560-7917.es2013.18.47.20638

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2012, 57% of Australians with HBV were diagnosed, 13% were linked into care following diagnosis and only 5% had received antiviral therapy 385 . Barriers to treatment include lack of awareness of the risks of HBV infection among patient populations, general practitioners, and health care workers [386][387][388][389][390][391][392] ; inadequate guidelines for diagnosis by general practitioners and referral to specialist services; and underdeveloped shared care pathways between specialists, primary care physicians and nurses for patients with HBV 393 .…”

Section: Barriers To Elimination[h3]mentioning

confidence: 99%

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

Cooke

Andrieux-Meyer

Applegate

et al. 2019

The Lancet Gastroenterology & Hepatology

445

391

View full text Add to dashboard Cite

investments to support countries with greatest burden of viral hepatitis All heavily burdened countries to have fully funded elimination plans by 2019 Recognition of need to focus on high burden countries and support for national policy development (All) Funding for national elimination plans Creation of fiscal space for new programmes with costed investment programmes Adopt domestic innovative finance tools where appropriate Support national policy makers in their activity (WHO, UNITAID, NGOs) Provide international support for financing measures (UNITAID, GFATM, bilaterial donors) Prevention Ensure all WHO elimination targets addressed in plans Address operational challenges in delivery of birth dose HBV vaccine Ensure provision of harm reduction services and engage with marginalised group (e.g. prisoners, PWIDs). Ensure clear public health messages to encourage testing and treatment Support countries to decriminalise injecting drug use and ensure equitable access to services for all (NGOs, WHO, civil society) Ensure appropriate funding for HBV vaccine, including birth dose (GAVI, WHO) Support R&D into HCV vaccine development (Research funders and pharma) Testing and Models of Care Focus on substantially scaling up testing for HBV and HCV Create and evaluate simplified care pathways relevant to local setting, integrating with existing services. Promote task sharing and decentralisation of care through capacity building, training and removal of Support operational research into simplified pathways (Research funders, UNITAID) requirements for specialised prescribing Diagnostics Ensure testing is integrated into the wider healthcare system, rather than centralised facilties Ensure access to quality diagnostics through Essential Diagnostic List and prequalification (WHO, funders) Support implementation science for models of care and R&D into novel diagnostics suitable for decentralised settings. (Research funders, FIND, industry) Access to treatment Ensure all Essential Medicines for viral hepatitis are included in national programmes, with an emphasis on pan-genotypic regimens Apply comprehensive policy approach to promoting access, including compulsory licensing Ensure all essential medicines are pre-qualified and either available through voluntary licensing or Medicines Patent Pool (WHO, NGOs, civil society, funders) Support shared procurement mechanisms for treatment (PAHO) Monitor Progress National plans need clearly defined, measurable objectives Develop new indices of national progress Progress of individual countries needs to be closely monitored towards elimination goals (Polaris, WHO, Creation of Elimination Index) Develop greater capacity for advocacy in high burden regions (all) Viral hepatitis is one of the leading causes of death in the world. 96% of those deaths are due to hepatitis B and C, which are the focus of this commission. Unlike many other major diseases, the tools exist to eliminate viral hepatitis. A highly effective vaccine is available to prevent hepatitis B, and a revolution in HCV treat...

show abstract

Section: Barriers To Elimination[h3]mentioning

confidence: 99%

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

Cooke

Andrieux-Meyer

Applegate

et al. 2019

The Lancet Gastroenterology & Hepatology

445

391

View full text Add to dashboard Cite

show abstract

“…Family names provide indirect information on ethnicity, as they typically differ per country. Indeed, family names have shown to be useful in identifying persons at risk for chronic HBV in low‐endemic countries . To determine ethnicity among Dutch donors, three independent researchers scored all donors who tested anti‐HBc only during first‐time anti‐HBc screening (n = 444) as “NW‐European,” “non–NW‐European,” or “inconclusive” based on their family name.…”

Section: Methodsmentioning

confidence: 99%

“…Indeed, family names have shown to be useful in identifying persons at risk for chronic HBV in low-endemic countries. 17 To determine ethnicity among Dutch donors, three independent researchers scored all VAN DE LAAR ET AL.…”

Section: Family Name-based Ethnicity Scoringmentioning

confidence: 99%

The yield of universal antibody to hepatitis B core antigen donor screening in theNetherlands, a hepatitis B virus low‐endemic country

et al. 2014

View full text Add to dashboard Cite

show abstract

Improving the identification of priority populations to increase hepatitis B testing rates, 2012

et al. 2015

View full text Add to dashboard Cite

BackgroundIt is estimated that over 40 % of the 218,000 people with chronic hepatitis B (CHB) in Australia in 2011 are undiagnosed. A disproportionate number of those with undiagnosed infection were born in the Asia-Pacific region. Undiagnosed CHB can lead to ongoing transmission and late diagnosis limits opportunities to prevent progression to hepatocellular carcinoma (HCC) and cirrhosis.Strategies are needed to increase testing for hepatitis B virus (HBV) (including culturally and linguistically diverse communities, Aboriginal and/or Torres Strait Islander (Indigenous) people and people who inject drugs). General practitioners (GPs) have a vital role in increasing HBV testing and the timely diagnosis CHB. This paper describes the impact of a GP-based screening intervention to improve CHB diagnosis among priority populations in Melbourne, Australia.MethodsA non-randomised, pre-post intervention study was conducted between 2012 and 2013 with three general practices in Melbourne, Australia. Using clinic electronic health records three priority populations known to be at increased CHB risk in Australia (1: Asian-born patients or patients of Asian ethnicity living in Australia; 2: Indigenous people; or 3): people with a history of injecting drugs were identified and their HBV status recorded. A random sample were then invited to attend their GP for HBV testing and/or vaccination. Baseline and follow-up electronic data collection identified patients that subsequently had a consultation and HBV screening test and/or vaccination.ResultsFrom a total of 33,297 active patients, 2674 (8 %) were identified as a priority population at baseline; 2275 (85.1 %) of these patients had unknown HBV status from which 338 (14.0 %) were randomly sampled. One-fifth (n = 73, 21.6 %) of sampled patients subsequently had a GP consultation during the study period; only four people (5.5 %) were subsequently tested for HBV (CHB detected in n = 1) and none were vaccinated against HBV.ConclusionCHB infection is an important long-term health issue in Australia and strategies to increase appropriate and timely testing are required. The study was effective at identifying whether Asian-born patients and patients of Asian had been tested or vaccinated for HBV; however the intervention was not effective at increasing HBV testing.

show abstract

A validation of the use of names to screen for risk of chronic hepatitis B in Victoria, Australia, 2001 to 2010

Cited by 4 publications

References 25 publications

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

The yield of universal antibody to hepatitis B core antigen donor screening in theNetherlands, a hepatitis B virus low‐endemic country

Improving the identification of priority populations to increase hepatitis B testing rates, 2012

Contact Info

Product

Resources

About